Session

Testis cancer: New surgical and medical approaches

Poster Session 02

  • Location:
    Room Milan (Hall B2, level 0)
  • Chairs:
     A. Lorch, Düsseldorf (DE)
     N. Nicolai, Milan (IT)
     J. Oldenburg, Lørenskog (NO)
  • Aims and objectives of this session

    This session will highlight and discuss controversial topics in the diagnosis and treatment of testicular tumours especially in stage II seminoma and will present new data on drugs used in the salvage chemotherapy setting.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 15
Minimally invasive RPLND(MI-RPLND): Is this an option for low volume stage 2 seminoma?

By: Nicol D., Huddart R., Reid A., Mayer E.

Institutes: Royal Marsden Hospital, Dept. of Urology, London, United Kingdom

* 16
Primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment

By: Lusch A., Zaum M., Besmens M., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

17
Single center experience with two cycles of PEB chemotherapy for clinical stage IIa or IIB seminoma patients

By: Kunit T.1, Törzsök P.1, Colleselli D.1, Sievert K.D.2

Institutes: 1Paracelsus Private University, Dept. of Urology, Salzburg, Austria, 2Universitätsklinikum Salzburg, Klinik für Urologie und Andrologie, Salzburg, Austria

18
Long-term oncologic outcomes of post-chemotherapy laparoscopic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours

By: Perez Reggeti J.I.1, Vigués F.2, Sanchez-Salas R.1, Linares Espinos E.1, Bonet X.2, Vila H.2, Secin F.3, Galiano M.1, Barret E.1, Rozet F.1, Cathelineau X.1

Institutes: 1Institute Mutualiste Montsouris, Dept. of Urology, Paris, France, 2Hospital Universitari De Bellvitge, Dept. of Urology, Barcelona, Spain, 3CEMIC, Dept. of Urology, Buenos Aires, Argentina

19
Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: Results from a multicenter study

By: Laclergerie F.1, Mouillet G.2, Balssa L.1, Larré S.3, Eschwege P.4, Hubert J.4, Saussine C.5, Cormier L.6, Thiery-Vuillemin A.2, Kleinclauss F.1

Institutes: 1University of Franche-Comté, Dept. of Urology, Besançon, France, 2University of Franche-Comté, Dept. of Oncology, Besançon, France, 3University of Reims Champagne-Ardenne, Dept. of Urology, Reims, France, 4University of Lorraine, Dept. of Urology, Nancy, France, 5University of Strasbourg, Dept. of Urology, Strasbourg, France, 6University of Bourgogne, Dept. of Urology, Dijon, France

20
Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01)

By: Necchi A.1, Raggi D.1, Giannatempo P.1, Calareso G.2, Togliardi E.3, Nicolai N.4, Crippa F.5, Mariani L.6, Salvioni R.4

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pharmacy , Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Clinical Epidemiology and Trials Organization, Milan, Italy

21
An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)

By: Necchi A.1, Magazzu’ D.2, Anichini A.3, Raggi D.1, Giannatempo P.1, Nicolai N.4, Colecchia M.5, Paolini B.5, Coradeschi E.6, Tassi E.3, Grazia G.3, Mortarini R.3, Calareso G.7, Togliardi E.8, Crippa F.9, Salvioni R.4, Gianni A.1, Valagussa P.6

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione Michelangelo, Dept. of Statistics, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Immunotherapy of Human Tumors, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, 6Fondazione Michelangelo, Head Office, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 8Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, 9Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy

22
Second-line combination chemotherapy with cisplatin, gemcitabine and paclitaxel for the treatment of advanced germ cell tumours

By: Tatsuro T., Yuasa T., Hagiwara K., Sano M., Uehara S., Ogawa M., Yamasaki M., Sakura M., Masuda H., Yamamoto S., Fukui I.

Institutes: Japanese Fundation For Cancer Research, Dept. of Urology, Koto-Ku, Japan

23
Risk stratification for venous thromboembolism in patients with testicular germ cell tumours

By: Bezan A.1, Posch F.1, Ploner F.1, Bauernhofer T.1, Pichler M.1, Szkandera J.1, Hutterer G.2, Pummer K.2, Gary T.3, Samonigg H.1, Gerger A.1, Stotz M.1

Institutes: 1Medical University of Graz, Dept. of Oncology, Graz, Austria, 2Medical University of Graz, Dept. of Urology, Graz, Austria, 3Medical University of Graz, Dept. of Angiology, Graz, Austria

24
Risk factors for thromboembolic complications in patients undergoing chemotherapy for metastatic germ cell tumors

By: Fankhauser C.1, Beyer J.2, Sander S.1, Poyet C1, Sulser T.1, Hermanns T.1

Institutes: 1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Oncology, Zurich, Switzerland

25
Impact of bleomycin (BLM) administration on the development of pulmonary toxicity in advanced germ cell tumours (GCT) receiving first-line chemotherapy (CT): A meta-analysis of randomized studies

By: Necchi A.1, Oualla K.2, Miceli R.3, Sonpavde G.4, Nicolai N.5, Raggi D.1, Giannatempo P.1, Boffi R.6, Busia A.6, Mariani L.3, Salvioni R.5

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Hassan II University Hospital, Dept. of Medical Oncology, Fez, Morocco, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 4UAB Comprehensive Cancer Center, Dept. of Medical Oncology, Birmingham, United States of America, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pneumology, Milan, Italy

Summary and context
 N. Nicolai, Milan (IT)